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Secretory phospholipase A2 increases SR-BI-mediated
selective uptake from HDL but not biliary
cholesterol secretion
Uwe J. F. Tietge,1,*,† Niels Nijstad,† Rick Havinga,† Julius F. W. Baller,† Fjodor H. van der Sluijs,†
Vincent W. Bloks,† Thomas Gautier,† and Folkert Kuipers†
Department of Medicine,* Campus Charite´ Mitte, Humboldt University, Berlin, Germany; and Center for
Liver, Digestive and Metabolic Diseases,† Laboratory of Pediatrics, University Medical Center Groningen,
Groningen, The Netherlands
Abstract High density lipoprotein cholesterol represents
a major source of biliary cholesterol. Secretory phospholi-
pase A2 (sPLA2) is an acute phase enzyme mediating de-
creased plasma HDL cholesterol levels. Clinical studies
reported a link between increased sPLA2 expression and the
presence of cholesterol gallstones. The aim of our study was
to investigate whether the overexpression of human sPLA2
in transgenic mice affects biliary cholesterol secretion and
gallstone formation. Liver weight (P , 0.01) and hepatic
cholesterol content (P , 0.01) were significantly increased
in sPLA2 transgenic mice compared with controls as a result
of increased scavenger receptor class B type I (SR-BI)-
mediated hepatic selective uptake of HDL cholesterol (P ,
0.01), whereas hepatic SR-BI expression remained un-
changed. However, biliary cholesterol secretion as well as
fecal neutral sterol and fecal bile salt excretion remained
unchanged in sPLA2 transgenic mice. Furthermore, gall-
stone prevalence in response to a lithogenic diet was iden-
tical in both groups. These data demonstrate that i)
increased flux of cholesterol from HDL into the liver via
SR-BI as a result of phospholipase modification of the HDL
particle translates neither into increased biliary and fecal
sterol output nor into increased gallstone formation, and ii)
increased sPLA2 expression in patients with cholesterol
gallstones might be a consequence rather than the under-
lying cause of the disease.—Tietge, U. J. F., N. Nijstad,
R. Havinga, J. F. W. Baller, F. H. van der Sluijs, V. W. Bloks,
T. Gautier, and F. Kuipers. Secretory phospholipase A2 in-
creases SR-BI-mediated selective uptake from HDL but not
biliary cholesterol secretion. J. Lipid Res. 2008. 49: 563–571.
Supplementary key words inflammation & reverse cholesterol trans-
port & high density lipoprotein & scavenger receptor class B type I
The protective effects of HDL against atherosclerotic
cardiovascular disease are generally ascribed to the central
role of the HDL particle in reverse cholesterol transport
(RCT) (1, 2). RCT in this context comprises the ability of
HDL to mediate the transport of excess cholesterol from
lipid-laden macrophages within the vascular wall back to
the liver for excretion into the bile, which represents the
major route for irreversible removal of cholesterol from
the body.
The acute phase protein secretory group IIA phospho-
lipase A2 (sPLA2) is a low molecular mass (14 kDa) enzyme
with exclusive phospholipase activity hydrolyzing phos-
pholipids at the sn -2 position (3, 4). Compared with wild-
type C57BL/6 controls that lack the endogenous mouse
sPLA2 enzyme as a result of a frameshift mutation (5),
human sPLA2 transgenic mice have significantly decreased
plasma HDL cholesterol levels, suggesting that sPLA2 is a
major mediator of the decreased plasma HDL cholesterol
invariably associated with acute as well as chronic inflam-
matory states (6–8). Patients with chronic inflammatory
diseases have a higher risk of developing atherosclerotic
cardiovascular disease (9, 10), and sPLA2 transgenic mice
develop atherosclerotic lesions even on a chow diet (11).
On the other hand, atherosclerosis itself is increasingly
recognized as a localized inflammatory condition within
the vessel wall (12, 13). The pathophysiological signifi-
cance of sPLA2 in this respect is underlined by studies
demonstrating increased circulating plasma levels of
sPLA2 to be predictive for acute coronary events (14–16).
The scavenger receptor class B type I (SR-BI) has been
identified as a key component in RCT mediating the
selective uptake of HDL cholesterol by the liver for sub-
sequent biliary excretion (17, 18). SR-BI knockout mice
and mice with attenuated hepatic SR-BI expression have
increased plasma HDL cholesterol levels and decreased
biliary cholesterol levels (19, 20). In contrast, hepatic over-
expression of SR-BI results in decreased plasma HDL
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cholesterol levels and increased biliary cholesterol ex-
cretion in response to acute overexpression (18) and also
in a transgenic mouse model (20). Hepatic SR-BI over-
expression is protective against atherosclerosis despite low
HDL cholesterol plasma levels acutely after adenovirus-
mediated gene transfer (21) and also using transgenic
mice (22). These studies suggest that the flux of choles-
terol from HDL into the liver via SR-BI might reflect func-
tional RCT more accurately than mere steady-state HDL
cholesterol plasma levels. sPLA2 modification of the HDL
particle stimulates selective uptake into the liver and the
adrenals in vivo (23). These data indicate that sPLA2 ex-
pression might affect hepatic cholesterol metabolism.
Therefore, the aim of the present study was to inves-
tigate the consequences of sPLA2-mediated HDL phos-
pholipid hydrolysis on hepatic cholesterol metabolism.
Our data demonstrate increased SR-BI-mediated cho-
lesterol flux from HDL into the liver in human sPLA2
transgenic mice, resulting in hepatic cholesterol storage.
However, neither biliary cholesterol secretion nor fecal
sterol excretion were affected under these conditions.
These results indicate that increased influx through SR-BI
into the liver might not be sufficient to enhance mass
RCT. These data might have important implications for




C57BL/6J control mice were obtained from Charles River
(Sulzfeld, Germany). The transgenic mice expressing human
group IIA sPLA2 driven by its endogenous promoter backcrossed
to the C57BL/6J genetic background for .14 generations have
been described previously (6, 24). The animals were caged in ani-
mal rooms with alternating 12 h periods of light (from 7:00 AM to
7:00 PM) and dark (from 7:00 PM to 7:00 AM), with ad libitum
access to water and mouse chow diet. Animal experiments were
performed in accordance with national laws. All protocols were
approved by the responsible ethics committee of the Landesamt
fu¨r Gesundheit, Erna¨hrung, und Technische Sicherheit Berlin.
Plasma lipid and lipoprotein analysis
Mice (n5 8 per group) were bled from the retro-orbital plexus
after a 4h fast usingheparinized capillary tubes.Aliquots of plasma
were stored at 220jC until analysis. Plasma total cholesterol,
triglycerides, and phospholipids were measured enzymatically
using commercially available reagents (Wako Pure Chemical
Industries, Neuss, Germany). HDL cholesterol levels were deter-
mined after precipitation of apolipoprotein B-containing lipo-
proteins using phosphotungstic acid-MgCl2 (Sigma Diagnostics,
St. Louis, MO).
HDL kinetic studies
Autologous apolipoprotein E-free HDL isolated by sequential
ultracentrifugation (1.063, d, 1.21) was prepared from pooled
mouse plasma and labeled with 125I-tyramine-cellobiose and
cholesteryl hexadecyl ether (cholesteryl-1,2-3H; New England
Nuclear Life Sciences Products) essentially as described (23), and
1 mCi of the 125I-tyramine-cellobiose-HDL and 1 million dpm of
the [3H]cholesteryl ether (CE)-HDL were injected via the tail
vein. Plasma decay curves for both tracers were generated by di-
viding the plasma radioactivity at each time point by the radio-
activity at the initial 5 min time point after tracer injection.
Fractional catabolic rates (FCRs) were determined from the area
under the plasma disappearance curves fitted to a bicompart-
mental model by use of the SAAM II program (23). Organ uptake
of HDL apolipoproteins (125I) and 3H-HDL-CEs was determined
and expressed as a percentage of the injected dose calculated by
multiplying the initial plasma counts (5 min time point) with the
estimated plasma volume (3.5% of total body weight). Selective
uptake into organs was determined by subtracting the percentage
of the injected dose of 125I-HDL recovered in each organ from
the percentage of the injected dose of [3H]HDL CE and cor-
recting the value for tissue weight. The hepatic uptake rate was
calculated as the product of the relative tissue FCR and the HDL
CE plasma pool, whereby the relative tissue FCR is represented
by the product of plasma FCR and the percentage of initial
plasma counts recovered in each organ. The HDL CE plasma
pool was determined by multiplying the plasma volume of each
mouse with the respective HDL CE concentration.
Cell culture and HDL selective uptake experiments
LdlA cells lacking LDL receptor expression and ldlA cells
stably transfected with a murine SR-BI cDNA (ldlA[mSR-BI])
were kindly provided by Dr. Monty Krieger (Massachusetts Insti-
tute of Technology, Boston, MA) and cultured as described (17).
For HDL uptake experiments, 5% lipoprotein-depleted serum
was used. A total of 10 mg/ml 125I/[3H]CE HDL isolated and
radioactively labeled as described above was added to the cells.
After a 5 h incubation, the cells were washed three times with PBS
(pH 7.4) and lysed with 0.5 ml of 0.1 M NaOH. Tracer uptake
was calculated as the counts recovered from the cells as a per-
centage of the total dose (counts from cells added to the counts
from medium). Selective HDL CE uptake was determined by
subtracting the percentage of the total dose of 125I recovered
from the cells from the percentage of the total dose of 3H re-
covered from the cells.
Analysis of liver lipid composition
The hepatic content of total and free cholesterol, phospho-
lipids, and triglycerides was measured as described (25). Protein
concentrations in liver homogenates were determined using the
BCA assay kit (Pierce).
Bile collection and assessment of biliary excretion of
cholesterol, phospholipids, and bile acids
Bile was collected by cannulation of the gallbladder under
Hypnorm(fentanyl/fluanisone;1ml/kg)anddiazepam(10mg/kg)
anesthesia, using a humidified incubator to maintain body
temperature. Bile collection was performed for 40 min, and
production was determined gravimetrically. Biliary bile salt,
cholesterol, and phospholipid concentrations were determined
and the respective biliary excretion rates calculated as described
previously (25).
Gallstone formation experiments
To investigate gallstone formation, groups of sPLA2 transgenic
mice (n 5 12) and C57BL/6 controls (n 5 15) were fed a litho-
genic diet containing 1.25% cholesterol, 15% total fat, and 0.5%
cholic acid (TD90221; Harlan Teklad, Madison, WI) for 5 weeks.
At the end of this period, the formation of macroscopic gall-
stones was assessed in fresh gallbladder bile. In separate ex-
periments, the effect of the lithogenic diet on bile flow and biliary
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cholesterol secretion was determined in the respective experi-
mental groups essentially as described above.
Analysis of gene expression by real-time quantitative PCR
Total RNA from mouse livers was isolated using Trizol
(Invitrogen) and quantified with Ribogreen (Molecular Probes,
Inc., Eugene, OR). cDNA synthesis was performed from 2 mg of
total RNA using reagents from Applied Biosystems (Darmstadt,
Germany). Real-time quantitative PCR was carried out using an
ABI-Prism 7700 (Applied Biosystems) sequence detector with the
default settings. PCR primers and fluorogenic probes were
designed with the Primer Express Software (Applied Biosystems)
and synthesized by Eurogentec (Seraing, Belgium). The mRNA
expression levels presented were calculated relative to the aver-
age of the housekeeping gene cyclophilin and further normal-
ized to the relative expression levels of the respective controls.
Isolation of liver plasma membranes and Western blot
for SR-BI
Liver plasma membranes were isolated using livers pooled
from three mice essentially as described previously (26). The
final membrane pellets were resuspended in buffer containing
250 mM sucrose and 10 mM Tris, pH 7.4, homogenized by
50 strokes through a Dounce homogenizer, and immediately
stored at280jC for further analysis. Protein concentrations were
determined using the BCA reagents (Pierce). Relative enrich-
ments of Na1/K1-ATPase and Mg21-ATPase as marker enzymes
for plasma membrane fractions were measured on an EL 808
Ultra Microplate Reader (Bio-Tek, Winooski, VT) to determine
the purity of the isolatedmembranes in the different preparations.
For Western blot analysis, protein samples from liver homogenates
(total cellular SR-BI content) and the plasma membrane fractions
(plasma membrane-associated SR-BI) were resolved on 10% SDS-
PAGE gels. mSR-BI was visualized using a polyclonal rabbit anti-
mSR-BI primary antibody (Novus Biologicals, Littleton, CO),
followed by the appropriate secondary antibody.
Fecal sterol analysis
Mice were housed individually, and feces was collected over a
period of 2 days. Fecal samples were lyophilized and weighed.
Aliquots thereof were used for the determination of neutral
and acidic sterol content by gas-liquid chromatography as de-
scribed (25).
Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS, Inc., Chicago, IL). Data
are presented as means 6 SEM. Statistical analysis was per-
formed using the Mann-Whitney U-test to compare different
groups. Statistical significance for all comparisons was assigned
at P , 0.05.
RESULTS
sPLA2 expression in transgenic mice results in decreased
plasma HDL cholesterol levels and increased hepatic
cholesterol content
Comparedwithwild-type controls, total cholesterol levels
in sPLA2 transgenic mice were decreased significantly
(766 4 vs. 956 5mg/dl;P, 0.01, n5 8),mainly as a result
of decreased plasma HDL cholesterol levels (49 6 3 vs.
74 6 4 mg/dl; P , 0.01, n 5 8). Plasma phospholipids
were also decreased significantly in sPLA2 transgenic mice
(128 6 9 vs. 192 6 5 mg/dl; P , 0.01, n 5 8), whereas
plasma triglycerides were not different between sPLA2
transgenic and wild-type control animals (606 10 vs. 546
7 mg/dl; P , 0.01, n 5 8). These data are consistent with
previous results (6).
Liver weight was increased significantly in sPLA2
transgenic mice compared with controls (1.70 6 0.06 vs.
1.41 6 0.06 g; P , 0.01). Hepatic cholesterol content per
gram of liver (6.23 6 0.26 vs. 5.50 6 0.13 mmol/g; P ,
0.05) (Table 1) as well as total hepatic cholesterol con-
tent (10.26 6 0.55 vs. 7.77 6 0.41 mmol/liver; P , 0.01)
(Table 1) were significantly higher in sPLA2 transgenic
mice compared with controls, which was entirely attrib-
utable to an increase in free cholesterol (P , 0.001)
(Table 1), whereas hepatic cholesteryl ester content did
not differ between groups (Table 1). Hepatic triglyceride
concentrations were decreased in sPLA2 transgenic mice
(8.7 6 0.6 vs. 16.3 6 3.3 mmol/g; P , 0.05) (Table 1),
whereas hepatic phospholipid concentrations did not dif-
fer between the experimental groups of mice (Table 1).
SR-BI-mediated selective uptake of HDL cholesteryl ester
is increased by sPLA2-mediated modification of the
particle in vivo and in vitro
To elucidate the metabolic basis of decreased plasma
HDL cholesterol levels and increased hepatic cholesterol
content in sPLA2 transgenic mice, we performed HDL
kinetic studies with autologous HDL. Fractional catabolic
rates for HDL apolipoproteins (0.212 6 0.021 vs. 0.085 6
0.004 pools/h; P , 0.001) as well as HDL CE (0.238 6
0.013 vs. 0.144 6 0.018 pools/h; P , 0.001) were sig-
nificantly higher in sPLA2 transgenic mice compared with
controls (see supplementary Fig. IA, IB).
In vivo, sPLA2-mediated modification of HDL particles
resulted in a significant increase of selective uptake into
organs with high expression of SR-BI, namely the liver
(30 6 2 vs. 41 6 3%/mg organ; P , 0.01) (Fig. 1A) and
the adrenals (57 6 7 vs. 89 6 10%/mg organ; P , 0.001)
(Fig. 1A). The mass HDL CE flux into livers of sPLA2
transgenic mice was increased significantly compared with
that in controls (44 6 3 vs. 68 6 5 mg/h/liver; P , 0.01)
(Fig. 1B). HDL apolipoprotein catabolism by the kidneys






Transgenic (n 5 8)
Total cholesterol mmol/g 5.50 6 0.13 6.23 6 0.26a
mmol/liver 7.77 6 0.41 10.26 6 0.55a
Free cholesterol mmol/g 4.03 6 0.15 4.83 6 0.21a
mmol/liver 2.08 6 0.16 2.30 6 0.14a
Cholesteryl ester mmol/g 1.47 6 0.08 1.41 6 0.09
mmol/liver 5.69 6 0.30 7.96 6 0.46
Phospholipids mmol/g 33.8 6 1.1 35.8 6 1.1
mmol/liver 47.7 6 2.4 59.0 6 2.9a
Triglycerides mmol/g 16.3 6 3.3 8.7 6 0.6a
mmol/liver 23.5 6 5.0 14.5 6 1.4
sPLA2, secretory phospholipaseA2. Values shown aremeans6SEM.
a Significantly different from wild-type mice (at least P , 0.05).
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of sPLA2 transgenic mice was increased significantly,
as indicated by increased negative selective uptake data
(226 6 3 vs. 214 6 2%/mg organ; P , 0.01) (Fig. 1A).
In addition, we performed experiments with HDL from
sPLA2 transgenic mice injected into controls (see supple-
mentary Fig. II). Consistent with the results obtained in
sPLA2 transgenic mice, the FCRs of sPLA2-modified HDL
in wild-type mice were higher than those for wild-type
HDL (HDL apolipoproteins, 0.1806 0.019 pools/h; HDL
CE, 0.214 6 0.017 pools/h), and selective uptake into the
liver (38 6 2%/mg organ) and adrenals (80 6 8%/mg
organ) as well as HDL protein clearance by the kidneys
(24 6 3%/mg organ) were increased.
To confirm that the increased selective uptake rates of
HDL CE in sPLA2 transgenic mice were attributable to
enzymatic modification of the HDL particle by sPLA2
and were mediated by SR-BI, in vitro studies were con-
ducted using ldlA cells stably transfected with a murine
SR-BI cDNA (Fig. 1C). In these cells, selective uptake from
sPLA2-modified HDL was 77% higher than the selective
uptake from wild-type HDL (356 6 vs. 626 6%/plate; P,
0.05) (Fig. 1C), whereas in ldlA cells not expressing SR-BI,
no appreciable selective uptake was detectable.
The hepatic gene expression pattern in sPLA2 transgenic
mice is consistent with increased cholesterol influx
and content
Compared with wild-type controls, hepatic mRNA ex-
pression of HMG-CoA reductase was decreased signifi-
cantly by 66% (relative expression levels, 1.00 6 0.06 vs.
0.34 6 0.03; P , 0.001) (Fig. 2A) and expression of the
LDL receptor was decreased significantly by 28% (relative
expression levels, 1.00 6 0.02 vs. 0.72 6 0.04; P , 0.01)
(Fig. 2A) in sPLA2 transgenic mice, consistent with in-
Fig. 1. Scavenger receptor class B type I (SR-BI)-mediated selective uptake of HDL cholesteryl ester is increased by secretory phospholipase
A2 (sPLA2) modification of the particle in vivo and in vitro. A: In vivo selective uptake rates of HDL cholesteryl ester into liver and adrenals
of sPLA2 transgenic mice and C57BL/6 controls. Homologous HDL particles were isolated from the indicated mice and labeled as
described in Materials and Methods. 125I-tyramine-cellobiose-labeled HDL uptake (percentage of the injected dose) was subtracted from
[3H]cholesteryl ether-labeled HDL uptake (percentage of the injected dose) into the indicated organs to calculate selective uptake per
microgram of tissue weight. Data are presented as means 6 SEM. B: In vivo rate of delivery of HDL cholesteryl ester (CE) into livers of
sPLA2 transgenic mice and C57BL/6 controls. From the data obtained from the kinetic experiments, hepatic uptake rates per hour
were calculated as described in Materials and Methods. Data are presented as means 6 SEM. * Statistically significant differences between
sPLA2 transgenic and wild-type mice (P, 0.05) as assessed by the Mann-Whitney U-test; n5 6 for each group. Data are presented as means
6 SEM. C: In vitro selective uptake of HDL cholesteryl esters was assessed by comparing HDL isolated from sPLA2 transgenic mice and
C57BL/6 controls and labeled identically as described for A. Experiments were performed as described in Materials and Methods
using ldlA cells lacking LDL receptors that were stably transfected with a murine SR-BI cDNA. Data are presented as means 6 SEM.
* Statistically significant differences between HDL from sPLA2 transgenic mice and wild-type controls (P , 0.05) as assessed by the Mann-
Whitney U-test. Shown is one representative example (n 5 3 for each condition) out of three independent experiments.
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creased hepatic cholesterol uptake and content. Further-
more, hepatic expression of sterol-regulatory element
binding protein-2 was decreased by 28% in sPLA2
transgenic mice (1.00 6 0.03 vs. 0.72 6 0.03; P , 0.001)
(Fig. 2A). In contrast, hepatic mRNA expression of ABCG5
(1.00 6 0.06 vs. 1.07 6 0.39; NS) (Fig. 2A) and ABCG8
(1.00 6 0.15 vs. 1.22 6 0.43; NS) (Fig. 2A) as well as of
SR-BI (1.00 6 0.04 vs. 0.91 6 0.04; NS) (Fig. 2A) were
unchanged in sPLA2 transgenic mice compared with con-
trols. Importantly, total hepatic SR-BI protein expression
and the amount of SR-BI associated with hepatic plasma
membranes also were unchanged in sPLA2 transgenic
mice (Fig. 2B). In addition, hepatic mRNA expression
of CD36 (1.00 6 0.06 vs. 0.93 6 0.17; NS) and LDL
receptor-related protein (1.00 6 0.05 vs. 0.89 6 0.05;
NS) were unchanged, whereas SR-A expression was de-
creased (1.00 6 0.03 vs. 0.81 6 0.03; P , 0.01) in sPLA2
transgenic mice.
Bile flow and biliary cholesterol excretion are unchanged
in sPLA2 transgenic mice
Next, we determined whether the increase in SR-BI-
mediated selective uptake of HDL cholesterol into livers of
sPLA2 transgenic mice translates into increased biliary
cholesterol secretion. Bile flow was unchanged in sPLA2
transgenic mice compared with controls (6.5 6 0.5 vs.
6.2 6 0.4 ml/min/100 g body weight, respectively; NS)
(Fig. 3A). However, biliary cholesterol secretion also
was unchanged in sPLA2 transgenic mice compared
with controls (2.2 6 0.3 vs. 1.7 6 0.4 nmol/min/100 g
body weight, respectively; NS) (Fig. 3B). In addition, no
differences were detected for biliary bile salt (194 6 20 vs.
155 6 37 nmol/min/100 g body weight, respectively;
NS) (Fig. 3B) or phospholipid secretion rates (32 6 2 vs.
26 6 4 nmol/min/100 g body weight, respectively; NS)
(Fig. 3B) in sPLA2 transgenic mice compared with wild-
type controls.
Fecal neutral sterol and bile salt excretion are unchanged
in sPLA2 transgenic mice
Fecal bile salt excretion (2.21 6 0.26 vs. 2.40 6
0.30 mmol/g; NS) (Fig. 4A) as well as fecal neutral sterol
excretion (3.58 6 0.20 vs. 3.74 6 0.25 mmol/g; NS)
(Fig. 4B) were unchanged in sPLA2 transgenic mice com-
pared with controls. These data demonstrate that in sPLA2
transgenic mice, total fecal sterol excretion is unchanged
despite increased hepatic SR-BI-mediated selective uptake
of HDL cholesteryl ester.
Gallstone formation is not increased in sPLA2
transgenic mice
Because clinical studies reported a positive association
between sPLA2 expression in the gallbladder epithelium
and the presence as well as the extent of cholesterol gall-
stone disease (27), we also assessed gallstone formation
in response to feeding a lithogenic diet in our experimen-
tal model. Both sPLA2 transgenic and control mice re-
sponded to feeding the lithogenic diet for 5 weeks with a
significant increase (each P , 0.001) in bile flow that was,
however, not different between the groups (15.0 6 2.6 vs.
18.6 6 3.5 ml/min/100 g body weight, respectively; NS).
Biliary cholesterol secretion increased dramatically as well,
but also without any difference between the experimental
groups (54 6 10 vs. 63 6 9 nmol/min/100 g body weight,
respectively; NS). Finally, consistent with the results ob-
tained on biliary cholesterol secretion, the development
of gallstones as assessed by polarization microscopy of
gallbladder bile also was identical in both groups of mice:
58% in sPLA2 transgenic mice (7 of 12; Fig. 5) and 67% in
the controls (10 of 15; Fig. 5).
DISCUSSION
The results of this study demonstrate that in sPLA2
transgenic mice, increased flux of HDL cholesterol into
the liver via the SR-BI-mediated selective uptake path-
way results in increased hepatic cholesterol storage and
adjustment of hepatic cholesterol synthesis, but it does
not translate into altered biliary cholesterol excretion in
the presence of unchanged hepatic expression of SR-BI,
ABCG5, and ABCG8.
In the process of RCT, hepatic SR-BI expression has
been identified as a major determinant of biliary choles-
Fig. 2. Gene expression levels in livers of sPLA2 transgenic mice
and wild-type C57BL/6 controls. A: mRNA expression deter-
mined by quantitative real-time PCR. Measurements were per-
formed as described in Materials and Methods. Data are presented
as means 6 SEM. * Statistically significant differences between
sPLA2 transgenic and control mice (P , 0.05) as assessed by the
Mann-Whitney U-test; n 5 6 for each group. A.U., arbitrary units;
HMGCoAR, HMG-CoA reductase; LDLR, LDL receptor; SREBP2,
sterol-regulatory element binding protein-2. B: Western blot
analysis of total hepatic SR-BI protein expression (homogenate)
and SR-BI localization to the plasma membrane (membrane) in
sPLA2 transgenic and control mice performed as described in
Materials and Methods.
sPLA2 and biliary cholesterol secretion 567
 at University of G











Supplemental Material can be found at:
terol excretion (28). Two possibilities exist for an altered
HDL cholesterol uptake via SR-BI into the liver: i) varying
hepatic SR-BI expression levels, and ii) lipase-mediated
modification of the HDL particle. i) SR-BI knockout mice
as well as mice with attenuated hepatic SR-BI expression
have decreased levels of biliary cholesterol excretion
(19, 20). Conversely, hepatic overexpression of SR-BI by
transgenic or recombinant adenovirus approaches re-
sulted in significantly increased biliary cholesterol excre-
tion (18, 20), consistent with the concept that increasing
hepatic protein levels of SR-BI promotes cholesterol elimi-
nation via the bile. ii) However, modification of the HDL
Fig. 4. Fecal excretion of neutral sterols and bile salts in sPLA2 transgenic mice and wild-type C57BL/6
controls. Feces were collected from groups of two to three mice for 24 h, and concentrations of bile salts
(A) and neutral sterols (B) were determined as described in Materials and Methods. Data are presented as
means 6 SEM; n 5 8 groups each.
Fig. 3. Bile flow and biliary secretion rates of phospholipids, cholesterol, and bile salts in sPLA2 transgenic
mice and wild-type C57BL/6 controls. A: Bile flow rates determined as described in Materials and Methods.
B: Biliary output rates of phospholipids, cholesterol, and bile salts. Bile was collected continuously for
40 min, substrate concentrations were determined within the bile as described in Materials and Methods,
and output rates were calculated accordingly. Data are presented as means 6 SEM; n 5 6 for each group.
BW, body weight.
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particle by lipases such as hepatic lipase (29) or sPLA2
(23, 30) renders the cholesteryl ester part of the HDL
particle more susceptible to selective uptake via the SR-BI
receptor pathway in the presence of unchanged SR-BI pro-
tein expression. In contrast to our findings in sPLA2 trans-
genic mice, hepatic lipase knockout mice had unchanged
hepatic cholesterol content and correspondingly also
unchanged hepatic HMG-CoA reductase expression (31).
The observed differencesmight conceivably be attributable
to the different substrate specificities of the enzymes, be-
cause sPLA2 acts, in contrast to hepatic lipase, exclusively
as a phospholipase. However, bile flow as well as biliary
secretion of cholesterol, bile salts, and phospholipids
remained unchanged in hepatic lipase knockout mice,
comparable to our data (31).
The unique feature of our model is that sPLA2 trans-
genic mice have an increased flux of HDL cholesterol into
the liver via SR-BI in the presence of low plasma HDL
cholesterol levels and unchanged hepatic SR-BI protein
expression. Our data demonstrate that increased flux via
SR-BI does not per se promote an increase in biliary cho-
lesterol excretion in the sPLA2 transgenic mouse. Instead,
a number of metabolic adaptations occur: i) increased
storage of cholesterol within significantly enlarged livers;
ii) dramatically decreased endogenous hepatic cholesterol
synthesis, as indicated by HMG-CoA receptor levels of only
one-third compared with controls; and iii) decreased LDL
uptake as a consequence of decreased LDL receptor ex-
pression. The differential regulation of different hepatic
metabolic and signaling pathways in sPLA2 transgenic
mice, namely the lack of effect on CE formation and liver
X receptor activation, and on the other hand decreased
expression of sterol-regulatory element binding protein-2
and its targets indicate the existence of different intra-
cellular cholesterol pools. A further investigation of the
nature of these pools will be the subject of future studies.
Our data might indicate that increased flux via SR-BI
in the presence of low plasma HDL levels does not nec-
essarily reflect increased RCT and therefore could not be
considered antiatherogenic. Indeed, sPLA2 transgenic
mice develop increased atherosclerosis (11). On the other
hand, as demonstrated by SR-BI overexpression models,
increased flux of HDL cholesterol into the liver via
increased hepatic SR-BI levels results in increased RCT
even in the presence of low plasmaHDL levels, as indicated
by increased biliary cholesterol excretion and decreased
atherosclerosis development (18, 20–22). Therefore, he-
patic expression levels of SR-BI and not the flux via this
receptor seem to be the major factor deciding the
intrahepatic fate of cholesterol.
Observations in other relevant mouse models seem to
support this conclusion. Apolipoprotein A-I knockout
mice have significantly decreased plasma HDL cholesterol
levels (32) but unchanged hepatic SR-BI expression (33).
Although kinetic studies clearly established decreased
HDL cholesterol delivery into the livers of apolipoprotein
A-I knockout mice (32), biliary cholesterol excretion
in these animals remained unaltered (20). Also, ABCA1
knockout mice have strongly decreased HDL cholesterol
plasma levels, unchanged hepatic SR-BI expression, and
unaltered biliary cholesterol excretion rates (25).
Recently, with the ABCG5/ABCG8 heterodimer, an-
other key component for biliary cholesterol excretion was
identified (34, 35). Both proteins have been shown to be
located at the canalicular membrane in hepatocytes, sug-
gesting that they are involved in biliary excretion. Func-
tional studies have further demonstrated that biliary
cholesterol secretion is reduced significantly in ABCG5/
ABCG8 knockout mice (36). In contrast, ABCG5/ABCG8
transgenic mice exhibit a significant increase in biliary
cholesterol output (37). In the sPLA2 transgenic model,
hepatic expression of ABCG5 and ABCG8 remained un-
changed compared with that in wild-type controls, as did
the biliary cholesterol secretion rates. These data indicate
that in the absence of changes in the expression levels of
these two important transporters, biliary cholesterol secre-
tion is unaltered in spite of increased rates of HDL cho-
lesterol influx into the liver.
Interestingly, sPLA2 has been detected in gallbladder
bile, and clinical studies reported an association between
cholesterol gallstone formation and sPLA2 levels in bile
(27). In a follow-up study, successful treatment of patients
with multiple cholesterol gallstones with ursodeoxycholic
acid resulted in decreased sPLA2 mRNA expression in the
gallbladder epithelium and lower sPLA2 protein levels in
bile (38). However, our results obtained in an experimen-
tal animal model of selective sPLA2 overexpression do not
support these human data: i) no direct effects of sPLA2 ex-
pression on cholesterol crystal or gallstone formation were
detected when feeding transgenic mice a lithogenic diet;
and ii) no indirect effects of sPLA2 through the modula-
tion of biliary cholesterol concentration were observed.
Although sPLA2 expression has profound effects on
plasma cholesterol metabolism and hepatic cholesterol
storage, neither biliary cholesterol levels nor secretion
Fig. 5. Gallstone formation in sPLA2 transgenic mice and wild-
type C57BL/6 controls. The indicated groups of mice were fed a
lithogenic diet for 5 weeks, then the formation of macroscopic gall-
stones was assessed as described in Materials and Methods. n 5 12
for sPLA2 transgenic mice and n 5 15 for C57BL/6 controls.
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were increased in sPLA2 transgenic mice compared with
C57BL/6 controls that lack expression of the endogenous
murine sPLA2 gene as a result of a frameshift mutation
(5). Therefore, our data indicate that increased sPLA2 ex-
pression in the gallbladder epithelium might be a conse-
quence rather than the cause of gallstone disease. It is
plausible that the expression of sPLA2 as an acute phase
protein increases in response to the proinflammatory en-
vironment of a gallbladder containing multiple choleste-
rol gallstones. However, because differences in bile acid
metabolism exist between humans and mice, we cannot
rule out a species-specific effect.
In summary, this study delineates the impact of sPLA2
on hepatic cholesterol metabolism. Increased influx
of HDL cholesterol via SR-BI into the liver by sPLA2-
mediated modification of the HDL particle, however, does
not translate into increased biliary cholesterol elimination
and therefore cannot be considered as indicative of in-
creased RCT. These results stress the importance of in-
creasing hepatic protein levels of SR-BI, ABCG5, and
ABCG8 when considering potential pharmacological tar-
gets to increase RCT.
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